Conference Track

Clinical Complications of HIV and Its Therapy

Source: CCO Official Conference Coverage of the 2008 International AIDS Conference

Capsule Summaries

REAL Study: Switch From Boosted PI to Boosted Atazanavir Has No Significant Effect on Lipohypertrophy at Week 48
Improved Survival Associated With HAART After TB Diagnosis
No Association Found Between Abacavir and CVD Risk in Analysis of Company-Sponsored Clinical Trials Database
Transient Elastometry Overestimates Liver Fibrosis Staging due to Liver Inflammation in HCV-Monoinfected Patients but Not in HCV/HIV-Coinfected Patients
Transient Elastography Used to Diagnosis Pseudo-Cryptogenic Liver Disease in Nonfibrotic, HIV-Infected Patients
Occult HBV Infection More Common in HIV-Positive Women vs Demographically Matched HIV-Negative Women
Pregabalin or Placebo Associated With Comparable Sensory Neuropathy Pain Scores at 14 Weeks in HIV-Infected Patients
Earlier Occurrence of Virologic Failure and Adverse Events Found in Patients Receiving Abacavir/Lamivudine vs Tenofovir/Emtricitabine in First-Line Antiretroviral Therapy
Analysis of SMART Data Consistent With D:A:D Finding That Abacavir Is Associated With Increased Risk for Cardiovascular Events
Distinct Sets of High-Risk HPV Genotypes Found in HIV-Infected Women in Seattle and Nairobi
HEAT: Comparable Virologic Suppression, Safety of First-Line Abacavir/Lamivudine vs Tenofovir/Emtricitabine at 96 Weeks
Phase III Trial Confirms Benefit of Tesamorelin in Decreasing VAT and Improving Body Image of HIV-Infected Patients With Lipodystrophy Associated With Antiretroviral Therapy

Expert Analysis

Clinical Complications of HIV and Its Therapy

Faculty:

Andrew Carr, MBBS, MD, FRACP
Donald P. Kotler, MD
Bruce Polsky, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize data concerning the cardiovascular, renal, metabolic, and neurologic complications associated with HIV and antiretroviral therapy
Discuss issues regarding the management of patients with HIV and coinfected with hepatitis B virus, human papillomavirus, or tuberculosis
Describe complications specific to certain HIV-infected populations such as women and men who have sex with men
Explain the efficacy and safety results associated with the use of abacavir/lamivudine vs tenofovir/emtricitabine in treatment-naive patients.

CREDIT INFORMATION

Release Date: 10/07/08

Expiration Date: 10/06/09

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.1 Nursing contact hours

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.